Navigation Links
Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor
Date:2/8/2010

Space Shuttle Endeavor lifted off from NASA’s Kennedy Space Center this morning, carrying on board the eighth scientific payload for Astrogenetix, a commercial biotech company created to use microgravity to develop the foundation of new medicines.

(Vocus) February 8, 2010 -- Space Shuttle Endeavor lifted off from NASA’s Kennedy Space Center this morning, carrying on board the eighth scientific payload for Astrogenetix, a commercial biotech company created to use microgravity to develop the foundation of new medicines.

“Conducting research in microgravity is so unique that we are able to learn things about these microbes that we could not learn on the ground,” said John Porter, Chief Executive Officer of Astrogenetix. “By observing genetic changes within the microbes, we are hoping to identify biomarkers that will lead to a successful vaccine or therapeutic.”

The Company’s payload on Flight STS-130 consists of methicillin-resistant Staphylococcus aureus (MRSA) microbes in search of a target for a vaccine or therapeutic. Research will build on information gained during experiments conducted on board previous shuttle missions performed over the past year. On STS-130, Astrogenetix will continue to interrogate specific genes within a group of genes that show promise for identifying a vaccine or therapeutic candidate, to further narrow the scope of virulence determinants.

“The launch of STS-130 allows us to add to our data on potential druggable targets in MRSA, and we appreciate the opportunity to work with NASA to conduct this important work,” added Dr. Jeanne Becker, Chief Science Officer for Astrogenetix.

Astrogenetix has worked closely with NASA in an effort to fully utilize the International Space Station, one of NASA’s primary priorities. The Company’s space-based research has been designated as National Lab Pathfinder Missions by NASA to demonstrate the use of the International Space Station as a research platform for commercial research and development.

“By utilizing the unique environment of microgravity, we believe we can shorten the time frame and reduce the cost of developing medicines,” said Thomas B. Pickens III, Astrogenetix’s Chairman of the Board. “The International Space Station National Lab provides an incredible platform to conduct breakthrough research.”

About Astrogenetix, Incorporated
A subsidiary of Astrotech Corporation (Nasdaq: ASTC), Astrogenetix is a biotechnology company formed to commercialize biotechnology products processed in the unique environment of microgravity. The Company offers a turn-key platform for pre-flight sample preparation, flight hardware, mission planning and operations, crew training and certification processes needed within the highly regulated and complex environment of manned space flight.

The statements in this document may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, continued government support and funding for key space programs, product performance and market acceptance of products and services, as well as other risk factors and business considerations described in the company's Securities & Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements.

###

Read the full story at http://www.prweb.com/releases/2010/02/prweb3580584.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
5. Signalife Continues to Procure Purchase Orders, Revenues
6. AQUISS Continues Expansion Into New Territory
7. Let there be light: new magnet design continues magnet labs tradition of innovation
8. Biotech Continues Upward Climb in October
9. SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations
10. Online Career Site for Life Science Professionals Continues Growth
11. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
Breaking Biology News(10 mins):